Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,678 | 2,241 | 2,288 | 17,724 | 17,356 |
| TOTAL | $4,937 | $2,735 | $3,582 | $18,432 | $17,737 |
| Non-Current Assets | |||||
| PPE Net | 159 | 306 | 507 | 678 | 294 |
| Intangibles | 0 | 42 | 211 | 380 | 8,512 |
| Other Non-Current Assets | 0 | 0 | 0 | 64 | 176 |
| TOTAL | $159 | $348 | $718 | $1,121 | $8,982 |
| Total Assets | $5,096 | $3,083 | $4,300 | $19,553 | $26,719 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 681 | 755 | 1,219 | 463 | 683 |
| Other current liabilities | N/A | N/A | 49 | 1,763 | 1,946 |
| TOTAL | $918 | $1,490 | $2,344 | $3,996 | $2,737 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 885 | 69 |
| TOTAL | $N/A | $N/A | $N/A | $885 | $1,676 |
| Total Liabilities | $918 | $1,490 | $2,344 | $4,881 | $4,413 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,888 | 206 | 41 | 12 | 6 |
| Common Shares | 11 | 1 | 2 | 21 | 7 |
| Retained earnings | -114,847 | -106,075 | -96,500 | -79,208 | -60,737 |
| Other shareholders' equity | -580 | -595 | -2,387 | -537 | -31 |
| TOTAL | $4,178 | $1,593 | $1,956 | $14,672 | $22,306 |
| Total Liabilities And Equity | $5,096 | $3,083 | $4,300 | $19,553 | $26,719 |